[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603354":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":47,"collaborators":50,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":20,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":29,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SERPINA1 'Z' heterozygotes","EXPERIMENTAL","Participants who are heterozygous for the SERPINA1 'Z' allele with either 0 or 2+ exacerbations in the previous year, and have not received pneumococcal vaccination within 5 years will be given PCV20.",[13],"Biological: 20-valent pneumococcal conjugate vaccine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","20-valent pneumococcal conjugate vaccine","Administration of PCV20",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"David LaFon, MD","CONTACT","2059343411","dlafon@uabmc.edu",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Birmingham","Alabama","35294","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-86.80249,33.52066,{"lat":39,"lon":38},[42,44],{"name":43,"role":24,"phone":25,"phoneExt":20,"email":26},"LaFon",{"name":45,"role":46,"phone":20,"phoneExt":20,"email":20},"David C LaFon, MD","PRINCIPAL_INVESTIGATOR",{"type":46,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"David Lafon","Assistant Professor",[51],{"name":52,"class":6},"Alpha-1 Foundation","100603354","phase-4-genetic-variation-in-igg-in-alpha-1-antitrypsin-deficiency-100603354",false,"NCT07135427","Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency","Genetic Variation in IgG as a Mechanism for Immune Deficiency and Exacerbations in AATD","IgG in AATD","Inclusion Criteria:\n\n* Adults who are heterozygous for a SERPINA1 Z allele\n* Have either had no COPD exacerbations or 2 or more exacerbations in the previous year\n* Has not received a pneumococcal conjugate vaccine within the past 5 years, or has only received the pneumococcal polysaccharide vaccine in the past\n\nExclusion Criteria:\n\n* Received a pneumococcal conjugate vaccine within the past 5 years\n* Known allergy, severe adverse reaction, or other sensitivity to pneumococcal conjugate vaccines","ALL","19 Years",{"count":64,"type":65},30,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections.\n\nTo investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.",[71,72,73],"Alpha 1-Antitrypsin","COPD","Antibody Deficiency","2025-11-05",{"date":76,"type":77},"2025-11-10","ACTUAL",{"date":79,"type":77},"2025-09-03",{"date":81,"type":65},"2027-06",{"name":5,"class":6},1]